安进公司15.5亿美元收购Dezima制药

  今天安进公司宣布以15.5亿美元收购Dezima制药公司，Dezima公司由阿姆斯特丹大学教授John Kastelein于2012年创立，该公司的主打产品是TA-8995，这是一种每日一次口服的胆固醇酯转移蛋白（CETP）抑制剂，用于治疗遭受心脏血管疾病的血脂异常患者。
  今年6月份，Dezima公司的研究数据就表明，TA-8995在单一疗法和他汀类药物联合疗法中都可以促进患者机体的低密度脂蛋白（坏胆固醇，LDL)水平降低，同时增加患者机体胆固醇的外排能力。
  安进公司以15.5亿美元获得了Dezima公司所有已发行的股票，而且这一收购项目已经获得了美国联邦贸易委员会(Federal Trade Commission)的批准；收购价格包括：300万的首笔支付费用，高达12.5亿的阶段性付款及产品销售净额的版权税。Dezima主席Sander Slootweg日前在一份声明中表示，Xention有限公司作为英国的投资公司，其可以帮助设计并且完成所需的临床前试验，并且最优化地进行产品的生产；而Dezima公司也非常适合安进公司，可以作为安进公司靶向高胆固醇产品开发的一大补充。
  今年8月27日，安进公司就透露表示，他们开发的每两周进行注射的降胆固醇药物Repatha？（evolocumab）已经获得FDA的批准，该药物是一种人类单克隆抗体，可以帮助抑制前蛋白转化酶枯草溶菌素9（PCSK9）同低密度脂蛋白受体（LDLR）的结合，而且安进公司已经将每月进行集中注射的申请进行了递交。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：
For Up to $1.55B, Amgen Acquires Dezima Pharma 

Amgen has agreed to acquire Dezima Pharma from Forbion Capital Partners for up to $1.55 billion-plus, Forbion said today. 

Dezima was founded in 2012 by John Kastelein, M.D., Ph.D., FESC, a professor at the Academic Medical Center of the University of Amsterdam; he serves as Dezima’s CSO. Dezima’s lead product is TA-8995, an oral, once-daily Cholesteryl Ester Transfer Protein (CETP) inhibitor for dyslipidemic patients suffering from cardiovascular disease (CVD). 

In June, Dezima’s TULIP (TA-8995: its use in patients with mild dyslipidemia) study showed that TA-8995, both as monotherapy and on top of statins, caused significant decrease of LDL and simultaneous increase of cholesterol efflux capacity, according to results published in The Lancet. 

Amgen has agreed to acquire all outstanding shares of Dezima for up to $1.55 billion from Forbion and other current shareholders, subject to obtaining U.S. Federal Trade Commission clearance. The acquisition price includes an upfront payment of $300 million, milestone payments of up to $1.25 billion and low-single-digit royalties on net product sales above an unspecified threshold. 

“Xention Ltd, one of our UK portfolio companies, designed and executed the required pre-clinical studies and optimized the manufacturing of the product,” Sander Slootweg, Forbion’s managing partner and chairman of Dezima, said in a statement. “Today’s acquisition and the value that Amgen has set on the company, validates our belief in the team and the science. Dezima will be a great fit for Amgen and complements its other products targeting high cholesterol.” 

On August 27, Amgen disclosed that it won FDA approval for the cholesterol-lowering, every-two-weeks injection drug Repatha™ (evolocumab), a human monoclonal antibody that inhibits the binding of proprotein convertase subtilisin/kexin type 9 (PCSK9) to the low-density lipoprotein (LDL) receptor (LDLR). Earlier this month, Amgen submitted an application with the agency for approval of a once-a-month injection dosage. 

Forbion helped to found, fund and staff the company, including in-licensing TA-8995 from Mitsubishi Tanabe Pharma. Mitsubishi Tanabe Pharma will receive an undisclosed portion of the upfront payment and future development and sales milestones from Dezima. Mitsubishi Tanabe Pharma will also retain development and commercialization rights to TA-8995 in certain territories in Asia, including Japan, Forbion said.